Suppr超能文献

亲缘单倍体供者减低强度预处理的造血干细胞移植治疗家族性噬血细胞性淋巴组织细胞增多症患儿

Hematopoietic stem cell transplantation with reduced intensity conditioning from a family haploidentical donor in an infant with familial hemophagocytic lymphohistocytosis.

机构信息

Department of Pediatrics, Osaka University Graduate School of Medicine, Yamadaoka 2-2, Suita, 565-0871, Japan.

Department of Pediatrics, Suita Municipal Hospital, Suita, Japan.

出版信息

Int J Hematol. 2011 Sep;94(3):285-290. doi: 10.1007/s12185-011-0916-6. Epub 2011 Aug 24.

Abstract

Allogeneic hematopoietic stem cell transplantation is the only curative method for patients with familial hemophagocytic lymphohistiocytosis (FHL). We present a case of a 3-month-old girl with Munc13-4 mutation (FHL3), who underwent bone marrow transplantation (BMT) from her human leukocyte antigen-haploidentical mother following reduced intensity conditioning (RIC) with fludarabine, melphalan, and busulfan. Engraftment after BMT was generally uneventful, with only mild acute graft versus host disease. Munc13-4 protein was restored following BMT, and she is well and free of disease 14 months after BMT. These results suggest that BMT with RIC from a family haploidentical donor may sufficiently restore immune regulation in infants, while lessening treatment-related mortality and long-term sequelae.

摘要

异基因造血干细胞移植是家族性噬血细胞性淋巴组织细胞增多症(FHL)患者的唯一治愈方法。我们报告了 1 例 Munc13-4 突变(FHL3)的 3 月龄女婴,在经过氟达拉滨、马法兰和白消安的减低强度预处理(RIC)后,接受了来自其人类白细胞抗原单倍体供体的骨髓移植(BMT)。BMT 后造血恢复通常无并发症,仅有轻度急性移植物抗宿主病。BMT 后 Munc13-4 蛋白得到恢复,BMT 后 14 个月,她无病生存且状况良好。这些结果表明,来自家族单倍体供体的 RIC-BMT 可能足以恢复婴儿的免疫调节,同时降低治疗相关死亡率和长期后遗症。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验